

EP04 / 51578



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

REC'D 20 AUG 2004

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03016759.7

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk



Europäisches  
Patentamt

European  
Patent Office

PCT/EP200 4 / 0 5 1 5 7 8

Office européen  
des brevets

Anmeldung Nr:  
Application no.: 03016759.7  
Demande no:

Anmeldetag:  
Date of filing: 23.07.03  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

ALTANA Pharma AG  
Byk-Gulden-Strasse 2  
78467 Konstanz  
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Alkaline salts

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Data/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K31/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT RO SE SI SK TR LI

1212EPORD01 2003-07 03

- 1 -

## Alkaline salts

### Subject matter of the invention

The present invention relates to alkaline salts of proton pump inhibitors. The novel salts can be used in the pharmaceutical industry for preparing medicaments.

### Technical background

Owing to their  $H^+/K^+$ -ATPase-inhibitory action, pyridin-2-ylmethylsulphonyl-1H-benzimidazoles, such as those known, for example, from EP-A-0005129, EP-A-0166287, EP-A-0174726 and EP-A-0268956, are of considerable importance in the therapy of disorders associated with an increased secretion of gastric acid.

Examples of active compounds from this group which are commercially available or in clinical development are 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphonyl]-1H-benzimidazole (INN: omeprazole), (S)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphonyl]-1H-benzimidazole (INN: esomeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulphonyl]-1H-benzimidazole (INN: lansoprazole), 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulphonyl]-1H-benzimidazole (INN: rabeprazole) and 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulphonyl]-1H-imidazo[4,5-b]pyridine (INN: tenatoprazole).

The abovementioned sulphonyl derivatives are, owing to their mechanism of action, also referred to as proton pump inhibitors or, abbreviated, as PPI.

### Prior art

For the first time, the European Patent Application 80602 describes the specific preparation of a sodium and of a calcium salt of a certain pyridin-2-ylmethylsulphonyl-1H-benzimidazole compound. Later on, the European Patent Application 124495 describes and claims novel salts of omeprazole with cations, such as the  $Li^+$ ,  $Na^+$ ,  $K^+$ ,  $Mg^{2+}$ ,  $Ca^{2+}$  or  $Ti^{4+}$  cation.

A common property of all of the abovementioned PPI is their sensitivity to acids (ultimately essential for effectiveness) which becomes apparent in their strong tendency to decompose in a neutral and in particular an acidic environment, giving rise to intensely coloured decomposition products. In the past, there has been no lack of considerable efforts, in spite of the sensitivity of the PPI to acids, to obtain stable and storable oral dosage forms comprising these PPI. A very common procedure to obtain stable oral PPI dosage forms, such as tablets, is the addition of an alkaline reacting compound, such as sodium carbonate, to the oral dosage form in order to render the micro-environment of the acid-

1212EPORD01 2003-07 03

- 2 -

labile PPI a pH of 7-12 (cf. European Patent 244380). Accordingly, stable and storable oral dosage forms (for example tablets or capsules) are now obtainable. However, the preparation of these oral dosage forms is relatively complicated, and with respect to the packaging too, certain complicated precautions have to be taken so that the dosage forms are sufficiently stable on storage even under extreme storage conditions (for example in tropical regions at high temperatures and high atmospheric humidity). Furthermore, in the past, there has been no lack of efforts to tailor the release of the PPI in the human body in the best possible manner to the respective requirements.

The international patent applications WO94/24887 and WO94/25028 claim the use of the compounds (-)- and (+)-pantoprazole for treating gastric disorders in humans. Each stereoisomer is said to have medical advantages compared to the respective other stereoisomers. The descriptions also mention a number of different possible salts of the stereoisomers, and particular preference is given to the sodium salt.

In international patent application WO94/27988, certain salts of (+)- and (-)-omeprazole and methods for their preparation are disclosed.

The international patent application WO97/41114 describes a certain process for preparing magnesium salts of pyridin-2-ylmethylsulphonyl-1H-benzimidazoles. What is described in an exemplary manner is, inter alia, the preparation of the magnesium salt of pantoprazole. According to the given analytical data, the salt that is prepared is pantoprazole magnesium in anhydrous form.

The international patent application WO00/10995 describes the dihydrate of the magnesium salt of racemic pantoprazole.

#### Description of the Invention

It has now been found that alkaline reacting salts of PPI can be produced, which on account of their properties and high stability are outstandingly suited for the further processing in oral dosage forms, even without addition of another alkaline reacting compound.

Accordingly, the invention provides in a general aspect alkaline reacting salts of pyridin-2-ylmethylsulphonyl-1H-benzimidazoles with  $H^+/K^+$ -ATPase-inhibitory activity.

According to the invention, "alkaline reacting salts" is understood to include pharmacologically compatible metal salts of pyridin-2-ylmethylsulphonyl-1H-benzimidazoles with  $H^+/K^+$ -ATPase-inhibitory activity, in which at least one positive charge equivalent of the metal ion is counterbalanced by a hydroxyl ion.

1212EPORD01 2003-07 03

- 3 -

According to the invention, "pyridin-2-ylmethylsulphonyl-1H-benzimidazoles with  $H^+/K^+$ -ATPase-inhibitory activity" is understood to include pantoprazole, omeprazole, lansoprazole, rabeprazole and tenatoprazole in racemic form, as well as the enantiomers of these compounds, such as (R)- and (S)-pantoprazole, (R)- and (S)-omeprazole, (R)- and (S)-lansoprazole, (R)- and (S)-rabeprazole and (R)- and (S)-tenatoprazole in pure form, mixtures thereof in any desired ratio, including in particular an enantiomer being substantially free of the respective other enantiomer.

In particular, the alkaline reacting salts of pyridin-2-ylmethylsulphonyl-1H-benzimidazoles with  $H^+/K^+$ -ATPase-inhibitory activity according to the invention can be characterized by the general formula 1



In which

Me is a pharmacologically acceptable two-valued metal ion,

PPI is a compound selected from pantoprazole, omeprazole, lansoprazole, rabeprazole and tenatoprazole and their enantiomers,

OH is a hydroxyl ion,

X is a positive, whole number from 1 to 3,

Y is a positive, whole number from 1 to 5 and

Z is a positive, whole number from 1 to 5,

whereby the equation  $(Y + Z) = 2X$  applies.

More particularly, the invention provides compounds of the formula 1,

In which

Me is a pharmacologically acceptable two-valued metal ion selected from magnesium, calcium and zinc,

PPI is a compound selected from pantoprazole, omeprazole, lansoprazole and rabeprazole and their enantiomers.

OH is a hydroxyl ion,

X is the number 1 or 2,

Y is a positive, whole number from 1 to 3 and

Z is a positive, whole number from 1 to 3,

whereby the equation  $(Y + Z) = 2X$  applies.

A preferred subject of the invention are compounds of the formula 1,

In which

Me is magnesium,

PPI is a compound selected from pantoprazole, (R)-pantoprazole and (S)-pantoprazole,

OH is a hydroxyl ion,

X is the number 1 or 2,

Y is the number 1 or 3 and

1212EPORD01 2003-07 03

- 4 -

Z is the number 1 or 3,

whereby the equation  $(Y + Z) = 2X$  applies.

A particular preferred subject of the invention are compounds of the formula 1,

in which

Me is magnesium,

PPI is (S)-pantoprazole, substantially free of (R)-pantoprazole,

OH is a hydroxyl ion,

X is the number 1 or 2,

Y is the number 1 or 3 and

Z is the number 1 or 3,

whereby the equation  $(Y + Z) = 2X$  applies.

It has now been found that the sodium salt of (-)- or (S)-pantoprazole, which is particularly preferred in the international patent application WO 94/24867, does not form a stable storage form. During attempts to obtain a stable oral dosage form for (-)-pantoprazole, it has now been found that alkaline reacting magnesium salts of (S)-pantoprazole, in particular in hydrate form, have highly surprising stability properties, making them particularly suitable candidates for use in solid or oral dosage forms. Compared to the sodium salt of (-)-pantoprazole, they have considerably improved stability properties. Thus, for example, the compound of formula 1, in which Me is magnesium, PPI is (S)-pantoprazole, X is 1, Y is 1 and Z is 1 in its hydrate form is, at 70°C, completely stable for one week and shows virtually no discolouration or decomposition, whereas over the same period of time and under identical conditions, the colour of the hydrate of (-)-pantoprazole sodium changes to brown, with formation of considerable amounts of decomposition products.

The compounds according to the invention and their hydrates can be used for the treatment and prevention of all disorders, which can be treated or prevented by using PPI. In particular, the compounds according to the invention and their hydrates can be used for treating gastric disorders. In this context, particular mention should be made of the relatively high stability of compounds according to the invention and their hydrates. For example, on storage under atmospheric conditions, the sum of by-products in  $[Mg][(S)\text{-pantoprazole}][OH] \cdot xH_2O$  remains virtually constant, whereas in the case of (-)-pantoprazole sodium, under identical conditions (storage at 60-70°C) the purity (according to HPLC) decreases from 99.5 to 96-97 %. This relatively high storage stability makes the compounds according to the invention and their hydrates particularly suitable for use in medicaments.

The compounds according to the invention and their hydrates are prepared in a specific manner by reacting the PPI with a Me-salt in the presence of an alkali-hydroxide, or from a readily soluble PPI salt (for example (-)-pantoprazole sodium), using for example a magnesium salt, such as magnesium chloride, an sodium hydroxide solution, in water or in mixtures of water with polar organic solvents (for example alcohols, preferably methanol, ethanol or isopropanol, or ketones, preferably acetone).

1212EPORD01 2003-07 03

- 5 -

Me-salts suitable for use in the process are, for example, Me-chloride, Me-bromide, Me-fluoride, Me-iodide, Me-formate, Me-acetate, Me-propionate, Me-gluconate or Me-carbonate. It is also possible to react Me-alkoxides (for example Me-methoxide, Me-ethoxide, Me-(iso)propoxide, Me-butoxide, Me-hexoxide or Me-phenoxide) in alcoholate medium with a readily soluble PPI salt in the presence of an alkali-hydroxide solution and to crystallise the alkaline PPI salt in its hydrate form by addition of water. Furthermore it is possible to recrystallise the compounds according to the invention and their hydrates from e.g. methanol/water mixtures.

The examples below illustrate the invention in more detail, without limiting it. m. p. denotes melting point, min. denotes minute(s), h denotes hour(s).

1212EPORD01 2003-07 03

- 8 -

**Examples****1. Magnesium [(5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphiny]-1H-benzimidazole) hydroxy monohydrate****Formula [Pantoprazole<sup>-</sup>OH<sup>-</sup> Mg<sup>2+</sup> H<sub>2</sub>O]: C<sub>15</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>6</sub>SMg**

10.7 g of pantoprazole sodium sesquihydrate are dissolved in 110 ml of water. 2.48 g of NaOH 40 % are added at 25 °C and the solution is stirred for 1 h. 5.01 g of magnesium chloride hexahydrate are dissolved in 20 ml of water, the solution is added drop wise under stirring at 25 °C to the pantoprazole sodium salt solution. Stirring is continued for 1 h. The resulting suspension is filtered with suction, the precipitate washed with 50 ml of water. The precipitate is re-suspended in 100 ml of water and again filtered and dried in a vacuum dryer (< 50 mbar) at 40 – 45 °C to give 10.76 g (94.6 %) of the title compound of m. p. 184-187 °C (decomposition) as off-white solid.

**Analysis:**

	expected	found
C	43,61	43,87
H	3,88	4,10
N	9,51	9,68
Mg	5,50	5,2

**2. Magnesium (-)-[(5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphiny]-1H-benzimidazole) hydroxy monohydrate****Formula [(S)-Pantoprazole<sup>-</sup>OH<sup>-</sup> Mg<sup>2+</sup> H<sub>2</sub>O]: C<sub>15</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>6</sub>SMg**

10.9 g of (-)-pantoprazole sodium salt are dissolved in 110 ml of water. 2.48 g of NaOH 40 % are added at 50 °C and the solution is stirred for 1 hour. The solution is cooled to room temperature. 5.01 g of magnesium chloride hexahydrate are dissolved in 20 ml of water. The magnesium chloride solution is added drop wise under stirring at 25 °C to the (-)-pantoprazole sodium salt solution. Stirring is continued for 18 h. The resulting suspension is filtered with suction, the precipitate washed with 50 ml of water. The precipitate is re-suspended in 100 ml of water and again filtered and dried in a vacuum dryer (< 50 mbar) at 40 – 45 °C to give 10.01 g (88.0 %) of the title compound of m. p. 164-167 °C (decomposition) as off-white solid

**Specific rotation:  $\alpha_D^{20} = -123$  (c= 0.5, methanol)****Analysis:**

	expected	found
C	43.51	43.88
H	3.88	4.16
N	9.51	9.63
Mg	5.50	5.6



1212EPORD01 2003-07 03

- 7 -

**3. Magnesium (+)-(5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methylsulphinyl)-1H-benzimidazole) hydroxy sesquihydrate**

Formula [2 (R)-Pantoprazole<sup>-</sup> 2OH<sup>+</sup> 2Mg<sup>2+</sup> 3H<sub>2</sub>O]: C<sub>23</sub>H<sub>23</sub>F<sub>4</sub>N<sub>6</sub>O<sub>11</sub>S<sub>2</sub>Mg<sub>2</sub>

5.0 g of (+)-pantoprazole sodium salt are dissolved in 50 ml of water. 1.23 g of NaOH 40 % are added at 35 °C and the solution is stirred for 1 h. The solution is cooled to room temperature. 2.50 g of magnesium chloride hexahydrate are dissolved in 15 ml of water. The magnesium chloride solution is added drop wise under stirring at 25 °C to the (+)-pantoprazole sodium salt solution. Stirring is continued for 18 h. The resulting suspension is filtered with suction, the precipitate washed in 3 portions with 50 ml of water and dried in a vacuum dryer (< 50 mbar) at 50 – 55 °C to give 4.33 g (74,6 %) of the title compound of m. p. 161-165 °C (decomposition) as off-white solid

Specific rotation:  $\alpha_D^{20} = +112$  (c= 0.5, methanol)

Analysis:

	expected	found
C	42.64	42.44
H	4.03	4.02
N	9.32	9.31

**4. Di-Magnesium tris-(5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methylsulphinyl)-1H-benzimidazole) hydroxy tetrahydrate**

Formula [3 Pantoprazole<sup>-</sup> OH<sup>-</sup> 2Mg<sup>2+</sup> 4H<sub>2</sub>O]: C<sub>43</sub>H<sub>41</sub>F<sub>6</sub>N<sub>9</sub>O<sub>17</sub>S<sub>3</sub>Mg<sub>2</sub>

25.0 g of pantoprazole sodium sesquihydrate are dissolved in 250 ml of water. 1.33 ml of NaOH 40 % are added at 25 °C and the solution is stirred for 15 min. 3.92 g of magnesium chloride hexahydrate are dissolved in 31 ml of water. The magnesium chloride solution is added drop wise under stirring at 25 °C to the pantoprazole sodium salt solution. Stirring is continued for 2.5 h. The resulting suspension is filtered with suction, the precipitate washed in 3 portions with 150 ml of water. The precipitate is dried in a vacuum dryer (< 50 mbar) at 40 – 45 °C to give 12.47 g (52.7 %) of the title compound of m. p. 182-185 °C (decomposition) as off-white solid.

Analysis:

	expected*	found
C	44,87	45,50
H	4,00	4,03
N	9,81	10,01
Mg	3,78	3,9

\*as tetrahydrate

1212EPORDM 2003-07 03

- 8 -

**6. DL-Magnesium (-)-tris-[(5-(difluoromethoxy))-2-[3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1H-benzimidazole] hydroxy pentahydrate****Formula [3 (S)-Pantoprazole<sup>-</sup> OH<sup>-</sup> 2Mg<sup>2+</sup> 5H<sub>2</sub>O]: C<sub>44</sub>H<sub>35</sub>F<sub>6</sub>N<sub>3</sub>O<sub>15</sub>S<sub>2</sub>Mg<sub>2</sub>**

8.0 g of (-)-pantoprazole sodium are dissolved in 60 ml of water. 0.49 g of NaOH 40 % are added at 30 - 35 °C and stirred for 15 min. 1.02 g of magnesium chloride hexahydrate are dissolved in 8 ml of water. The magnesium chloride solution is added drop wise under stirring at 25 °C to the (-)-pantoprazole sodium salt solution. Stirring is continued for 18 h. The resulting suspension is filtered with suction, the precipitate washed in 2 portions with 50 ml of water. The precipitate is dried in a vacuum dryer (< 50 mbar) at 60 °C to give 2.41 g (48.3 %) of the title compound of m. p. 162-168°C (decomposition) as off-white solid.

Specific rotation:  $\alpha_D^{20} = -125$  (c= 0,5 in Methanol)

Analysis:

	expected*	found
C	44,25	44,34
H	4,10	4,29
N	9,68	9,80

\*as pentahydrate

**6. DL-Magnesium (+)-tris-[(5-(difluoromethoxy))-2-[3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1H-benzimidazole] hydroxy pentahydrate****Formula [3 (R)-Pantoprazole<sup>-</sup> OH<sup>-</sup> 2Mg<sup>2+</sup> 5H<sub>2</sub>O]: C<sub>44</sub>H<sub>35</sub>F<sub>6</sub>N<sub>3</sub>O<sub>15</sub>S<sub>2</sub>Mg<sub>2</sub>**

5.0 g of (+)-pantoprazole sodium are dissolved in 50 ml of water. 0.27 ml of NaOH 40 % are added at 30 - 35 °C and the solution is stirred for 15 min. 0.78 g of magnesium chloride hexahydrate are dissolved in 8 ml of water. The magnesium chloride solution is added drop wise under stirring at 25 °C to the (+)-pantoprazole sodium salt solution. Stirring is continued for 2 days. The resulting suspension is filtered with suction, the precipitate washed in 3 portions with 25 ml of water. The precipitate is dried in a vacuum dryer (< 50 mbar) at 40 °C to give 2.10 g (40.1 %) of the title compound of m. p. 161-166°C (decomposition) as off-white solid.

Specific rotation:  $\alpha_D^{20} = +114,5$  (c= 0.5 in Methanol)

Analysis:

	expected*	found
C	44,25	44,81
H	4,10	4,05
N	9,68	9,79
Mg	3,73	4,2

\*as pentahydrate

1212EPORD01 2003-07 03

- 9 -

**Commercial utility**

The compounds according to the invention and their hydrates have useful pharmacological properties, rendering them commercially utilizable. In particular, they have a pronounced inhibitory effect on the secretion of gastric acid and excellent gastrointestinal protective action in warm-blooded animals, in particular man. Due to their unique stability characteristics, the compounds according to the invention and their hydrates are particularly suited for the production of stable oral PPI dosage forms. By the presence of the hydroxyl ion in the compounds according to the invention, the PPI, which are acid-labile and susceptible to traces of acid, have a self-protection against undesired decomposition on storage.

In context of the invention, "gastrointestinal protection" is to be understood as the prevention and treatment of gastrointestinal disorders, in particular gastrointestinal inflammatory disorders and lesions (such as, for example, Ulcus ventriculi, Ulcus duodeni, gastritis, irritable bowel owing to an increased production of acid or as a result of medicaments, GERD, Crohn's disease, IBD) which may be caused, for example, by microorganisms (for example *Helicobacter pylori*), bacterial toxins, medicaments (for example certain antiphlogistics and antirheumatic drugs), chemicals (for example ethanol), gastric acid or stress.

With their excellent properties, selected compounds according to the invention and their hydrates are, in various models for the determination of antilulcerogenic and antisecretory properties, surprisingly clearly superior to the prior-art compounds, in particular with respect to their stability and their pharmacological properties. Owing to these properties, the compounds  $[Mg]((S)\text{-pantoprazole})[OH] \cdot xH_2O$  and  $[Mg]_2((S)\text{-pantoprazole})_2[OH] \cdot xH_2O$  for example are highly suitable for use in human and veterinary medicine, where they are used, in particular, for the treatment and/or prophylaxis of gastrointestinal disorders.

Accordingly, the invention furthermore provides compounds according to the invention and their hydrates for use in the treatment and/or prophylaxis of the abovementioned diseases.

The invention also embraces the use of compounds according to the invention and their hydrates for preparing medicaments used for the treatment and/or prophylaxis of the abovementioned diseases.

Furthermore, the invention embraces the use of compounds according to the invention and their hydrates for the treatment and/or prophylaxis of the abovementioned diseases.

The invention also provides medicaments comprising compounds according to the invention and their hydrates.

1212EPORD01 2003-07 03

- 10 -

The medicaments are prepared by processes known per se which are familiar to the person skilled in the art. As medicaments, the compounds according to the invention and their hydrates are employed either as such or, preferably, in combination with suitable pharmaceutical auxiliaries or carriers in the form of tablets, coated tablets, capsules, suppositories, plasters (for example as TTS), emulsions, suspensions or solutions, where the content of active compound is advantageously from 0.1 to 95% and where it is possible to produce pharmaceutical dosage forms (for example flow-release forms or enteric forms) which, by the appropriate choice of auxiliaries and carriers, are tailored for the active compound and/or the desired onset of action and/or the duration of action.

The auxiliaries or carriers suitable for the desired pharmaceutical formulations are known to the person skilled in the art owing to his expert knowledge. In addition to solvents, gel formers, suppository bases, tableting auxiliaries and other carriers for active compounds, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavour-masking agents, preservatives, solubilizers, colorants or, in particular, permeation promoters and complex formers (for example cyclodextrins).

The compounds according to the invention and their hydrates can be administered orally, parenterally or percutaneously.

In human medicine, it has generally been found to be advantageous to administer the compounds according to the invention and their hydrates, when given orally, in a daily dose of from about 0.1 to 2, preferably 0.2 to 1.5 and in particular 0.3 to 1.1, mg/kg of body weight [based on the PPI], if appropriate in the form of a plurality of, preferably 1 to 4, individual doses, to obtain the desired result. For parenteral treatment, it is possible to use similar or (in particular when the active compounds are administered intravenously) generally lower dosages. The optimum dosage and the type of administration of the active compounds required in each case can easily be determined by the person skilled in the art, owing to his expert knowledge.

A further aspect of the invention is thus a medicament, comprising a compound according to the invention or its hydrate together with customary auxiliaries, where the single dose comprises from 10 to 100 mg of PPI.

A further aspect of the invention is a medicament, comprising a compound according to the invention or its hydrate together with customary auxiliaries, where the single dose comprises from 20 to 80 mg of (-)-pantoprazole.

A further aspect of the invention is the use of a compound according to the invention or its hydrate for treating gastrointestinal disorders.

A further aspect of the invention is the use of a compound according to the invention or its hydrate for treating gastrointestinal disorders in patients who are slow metabolizers.

1212EPORD01 2003-07 03

- 11 -

A further aspect of the invention is the use of a compound according to the invention or its hydrate for treating gastrointestinal disorders in patients who have a risk for drug interactions.

A further aspect of the invention is the use of a compound according to the invention or its hydrate for treating gastrointestinal disorders in patients who need an inhibition of acid secretion for a longer period of time.

A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who are slow metabolizers, comprising a compound according to the invention or its hydrate together with customary auxiliaries, where the single dose comprises from 10 to 100 mg of the PPI.

A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who are slow metabolizers, comprising a compound according to the invention or its hydrate together with customary auxiliaries, where the single dose comprises from 20 to 80 mg of the PPI.

A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who have a risk for drug interactions, comprising a compound according to the invention or its hydrate together with customary auxiliaries, where the single dose comprises from 10 to 100 mg of the PPI.

A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who have a risk for drug interactions, comprising a compound according to the invention or its hydrate together with customary auxiliaries, where the single dose comprises from 20 to 80 mg of the PPI.

A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who need an inhibition of acid secretion for a longer period of time, comprising a compound according to the invention or its hydrate together with customary auxiliaries, where the single dose comprises from 10 to 100 mg of the PPI.

A further aspect of the invention is a medicament for treating gastrointestinal disorders for use in patients who need an inhibition of acid secretion for a longer period of time, comprising a compound according to the invention or its hydrate together with customary auxiliaries, where the single dose comprises from 20 to 80 mg of the PPI.

If a compound according to the invention or its hydrate is to be used for treating the abovementioned diseases, the pharmaceutical preparations may also comprise one or more pharmacologically active ingredients from other groups of medicaments. Examples which may be mentioned are: tranquilizers (for example from the group of the benzodiazepines, e. g. diazepam), spasmolytic drugs (e. g. bletamverine or camylofine), anticholinergic drugs (e. g. oxyphencyclimine or phencarbamide), local anesthetics (e. g. tetracaine or procaine), optionally also enzymes, vitamins or amino acids.

1212EPORD01 2003-07 03

- 12 -

In this context, particular emphasis is given to the combination of the compounds according to the invention with other pharmaceuticals which buffer or neutralize gastric acid or which inhibit the secretion of acid, such as, for example, antacids (such as, for example, magaldrate) or H<sub>2</sub> blockers (e. g. cimetidine, ranitidine), and with gastrin antagonists with the aim to enhance the main action in an additive or superadditive sense and/or to eliminate or reduce side-effects or to obtain a more rapid onset of action. Mention may also be made of the fixed or free combination with NSAIDs (such as, for example, etofenamate, diclofenac, indometacin, ibuprofen or piroxicam) for preventing the gastrointestinal damage caused by the NSAIDs, or with antibacterial substances (such as, for example, cephalosporins, tetracyclins, penicillins, macrolides, nitroimidazoles or else bismuth salt) for controlling *Helicobacter pylori*. Antibacterial combination partners which may be mentioned are, for example, mezlocillin, ampicillin, amoxicillin, cefalothin, cefoxitin, cefotaxim, imipenem, gentamycin, amikacin, erythromycin, ciprofloxacin, metronidazole, clarithromycin, azithromycin and combinations thereof (e. g. clarithromycin + metronidazole or amoxicillin + clarithromycin).

1212EPORD01 2003-07 03

- 13 -

**Claims**

1. Pharmacologically compatible metal salts of pyridin-2-ylmethylsulphonyl-1H-benzimidazoles with  $H^+/K^+$ -ATPase-inhibitory activity, in which at least one positive charge equivalent of the metal ion is counterbalanced by a hydroxyl ion, and hydrates thereof.

2. Pharmacologically compatible metal salts according to claim 1, in which the pyridin-2-ylmethylsulphonyl-1H-benzimidazoles with  $H^+/K^+$ -ATPase-inhibitory activity is selected from the group of pantoprazole, omeprazole, lansoprazole, rabeprazole and tenatoprazole, (R)- and (S)-pantoprazole, (R)- and (S)-omeprazole, (R)- and (S)-lansoprazole, (R)- and (S)-rabeprazole and (R)- and (S)-tenatoprazole, and hydrates thereof.

3. Pharmacologically compatible metal salts according to claim 1, characterized by the general formula 1



in which

Me is a pharmacologically acceptable two-valued metal ion.

PPI is a compound selected from pantoprazole, omeprazole, lansoprazole, rabeprazole and tenatoprazole and their enantiomers,

OH is a hydroxyl ion,

X is a positive, whole number from 1 to 3,

Y is a positive, whole number from 1 to 5 and

Z is a positive, whole number from 1 to 6,

whereby the equation  $(Y + Z) = 2X$  applies, and hydrates thereof.

4. Pharmacologically compatible metal salts according to claim 1, characterized by the general formula 1 of claim 3. in which

Me is a pharmacologically acceptable two-valued metal ion selected from magnesium, calcium and zinc,

PPI is a compound selected from pantoprazole, omeprazole, lansoprazole and rabeprazole and their enantiomers,

OH is a hydroxyl ion,

X is the number 1 or 2,

Y is a positive, whole number from 1 to 3 and

Z is a positive, whole number from 1 to 3.

whereby the equation  $(Y + Z) = 2X$  applies, and hydrates thereof.

1212EPORD01 2003-07 03

- 14 -

5. Pharmacologically compatible metal salts according to claim 1, characterized by the general formula 1 of claim 3, in which  
Me is magnesium,  
PPI is a compound selected from pantoprazole, (R)-pantoprazole and (S)-pantoprazole,  
OH is a hydroxyl ion,  
X is the number 1 or 2,  
Y is the number 1 or 3 and  
Z is the number 1 or 3,  
whereby the equation  $(Y + Z) = 2X$  applies, and hydrates thereof.
6. Pharmacologically compatible metal salts according to claim 1, characterized by the general formula 1 of claim 3, in which  
Me is magnesium,  
PPI is (S)-pantoprazole,  
OH is a hydroxyl ion,  
X is the number 1 or 2,  
Y is the number 1 or 3 and  
Z is the number 1 or 3,  
whereby the equation  $(Y + Z) = 2X$  applies, and hydrates thereof.
7. Pharmacologically compatible metal salt according to claim 1, which is  $Mg[Pantoprazole]OH$ , and hydrates thereof.
8. Pharmacologically compatible metal salt according to claim 1, which is  $Mg[(S)-Pantoprazole]OH$ , and hydrates thereof.
9. Pharmacologically compatible metal salt according to claim 1, which is  $Mg_2[Pantoprazole]_3OH$ , and hydrates thereof.
10. Pharmacologically compatible metal salt according to claim 1, which is  $Mg_2[(S)-Pantoprazole]_3OH$ , and hydrates thereof.
11. Medicament, comprising a compound according to any of claims 1 to 10 together with customary auxiliaries.
12. Use of a compound according to any of claims 1 to 10 for treating gastrointestinal disorders.



1212EPORD01 2003-07 03

- 15 -

**Abstract**

The invention relates to alkaline salts of proton pump inhibitors and to medicaments comprising these compounds.